110 related articles for article (PubMed ID: 21385481)
1. Parallel determination of NeuroD1, chromogranin-A, KI67 and androgen receptor expression in surgically treated prostate cancers.
Cindolo L; Cantile M; Franco R; Chiodini P; Schiavo G; Forte I; Zlobec I; Salzano L; Botti G; Gidaro S; Terracciano L; Cillo C
Int Braz J Urol; 2011; 37(1):57-66. PubMed ID: 21385481
[TBL] [Abstract][Full Text] [Related]
2. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
[TBL] [Abstract][Full Text] [Related]
3. NeuroD1 expression in human prostate cancer: can it contribute to neuroendocrine differentiation comprehension?
Cindolo L; Franco R; Cantile M; Schiavo G; Liguori G; Chiodini P; Salzano L; Autorino R; Di Blasi A; Falsaperla M; Feudale E; Botti G; Gallo A; Cillo C
Eur Urol; 2007 Nov; 52(5):1365-73. PubMed ID: 17126478
[TBL] [Abstract][Full Text] [Related]
4. Expression of store-operated channel components in prostate cancer: the prognostic paradox.
Perrouin Verbe MA; Bruyere F; Rozet F; Vandier C; Fromont G
Hum Pathol; 2016 Mar; 49():77-82. PubMed ID: 26826413
[TBL] [Abstract][Full Text] [Related]
5. Prognostic relevance of proliferation markers (Ki-67, PHH3) within the cross-relation of ERG translocation and androgen receptor expression in prostate cancer.
Goltz D; Montani M; Braun M; Perner S; Wernert N; Jung K; Dietel M; Stephan C; Kristiansen G
Pathology; 2015 Dec; 47(7):629-36. PubMed ID: 26517642
[TBL] [Abstract][Full Text] [Related]
6. Human ASH1 expression in prostate cancer with neuroendocrine differentiation.
Rapa I; Ceppi P; Bollito E; Rosas R; Cappia S; Bacillo E; Porpiglia F; Berruti A; Papotti M; Volante M
Mod Pathol; 2008 Jun; 21(6):700-7. PubMed ID: 18311112
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer.
Segawa N; Mori I; Utsunomiya H; Nakamura M; Nakamura Y; Shan L; Kakudo K; Katsuoka Y
Pathol Int; 2001 Jun; 51(6):452-9. PubMed ID: 11422807
[TBL] [Abstract][Full Text] [Related]
8. Localization of immunoreactive HIF-1alpha and HIF-2alpha in neuroendocrine cells of both benign and malignant prostate glands.
Monsef N; Helczynski L; Lundwall A; Påhlman S;
Prostate; 2007 Aug; 67(11):1219-29. PubMed ID: 17562539
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer.
Jeetle SS; Fisher G; Yang ZH; Stankiewicz E; Møller H; Cooper CS; Cuzick J; Berney DM;
Virchows Arch; 2012 Aug; 461(2):103-7. PubMed ID: 22767265
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications.
Theodoropoulos VE; Tsigka A; Mihalopoulou A; Tsoukala V; Lazaris AC; Patsouris E; Ghikonti I
Urology; 2005 Oct; 66(4):897-902. PubMed ID: 16230178
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of neuroendocrine differentiation in patients with Gleason score 8-10 prostate cancer treated with primary radiotherapy.
Krauss DJ; Hayek S; Amin M; Ye H; Kestin LL; Zadora S; Vicini FA; Cotant M; Brabbins DS; Ghilezan MI; Gustafson GS; Martinez AA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e119-25. PubMed ID: 21596486
[TBL] [Abstract][Full Text] [Related]
12. Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate.
Krupski T; Petroni GR; Frierson HF; Theodorescu JU
Urology; 2000 May; 55(5):743-9. PubMed ID: 10792093
[TBL] [Abstract][Full Text] [Related]
13. Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis.
Diallo JS; Aldejmah A; Mouhim AF; Fahmy MA; Koumakpayi IH; Sircar K; Bégin LR; Mes-Masson AM; Saad F
BJU Int; 2008 May; 101(10):1302-9. PubMed ID: 18294307
[TBL] [Abstract][Full Text] [Related]
14. Survival predictors in patients with prostate adenocarcinoma with hormonal blockade.
Angulo JC; Redondo C; Sánchez-Chapado M; Colás B; Ropero S; López JI
Pathol Res Pract; 2016 Oct; 212(10):899-903. PubMed ID: 27502465
[TBL] [Abstract][Full Text] [Related]
15. Expression of pS2 in prostate cancer correlates with grade and Chromogranin A expression but not with stage.
Ather MH; Abbas F; Faruqui N; Israr M; Pervez S
BMC Urol; 2004 Dec; 4(1):14. PubMed ID: 15588310
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy.
Sadi MV; Walsh PC; Barrack ER
Cancer; 1991 Jun; 67(12):3057-64. PubMed ID: 1710537
[TBL] [Abstract][Full Text] [Related]
17. Correlation of androgen receptor status, neuroendocrine differentiation and angiogenesis with time-to-biochemical failure after radical prostatectomy in clinically localized prostate cancer.
Revelos K; Petraki C; Scorilas A; Stefanakis S; Malovrouvas D; Alevizopoulos N; Kanellis G; Halapas A; Koutsilieris M
Anticancer Res; 2007; 27(5B):3651-60. PubMed ID: 17972531
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors.
Wafa LA; Palmer J; Fazli L; Hurtado-Coll A; Bell RH; Nelson CC; Gleave ME; Cox ME; Rennie PS
Hum Pathol; 2007 Jan; 38(1):161-70. PubMed ID: 16997353
[TBL] [Abstract][Full Text] [Related]
19. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.
Sainio M; Visakorpi T; Tolonen T; Ilvesaro J; Bova GS
Pathol Res Pract; 2018 Jun; 214(6):848-856. PubMed ID: 29728311
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population.
Inoue T; Segawa T; Shiraishi T; Yoshida T; Toda Y; Yamada T; Kinukawa N; Kinoshita H; Kamoto T; Ogawa O
Urology; 2005 Aug; 66(2):332-7. PubMed ID: 16098362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
